English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

To prepare polymer-drug conjugates containing a combination of memantine, tacrine, and  E )- N -(3-aminopropyl)cinnamide, promising therapeutics for the treatment of neurodegenerative disorders. The conjugates were characterised by  1 HNMR, particle size analysis, SEM, LC-MS, TEM/EDX, and XRD, followed by  in vitro  anti-acetylcholinesterase and drug release studies. 1 H NMR analysis revealed successful drug conjugation with drug mass percentages in the range of 1.3–6.0% w/w. The drug release from the conjugates was sustained for 10 h in the range of 20–36%. The conjugates’ capability to inhibit acetylcholinesterase (AChE) activity was significant with IC 50  values in the range of 13–44.4 µm which was more effective than tacrine (IC 50  =1698.8 µm). The docking studies further confirmed that the conjugation of the drugs into the polymer improved their anti-acetylcholinesterase activity. The drug release profile, particle sizes, and  in vitro  studies revealed that the conjugates are promising therapeutics for treating neurodegenerative disorders.

Polymer drug conjugates containing memantine, tacrine and cinnamic acid: promising nanotherapeutics for the treatment of Alzheimer’s disease